Glucagon News and Research

RSS

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and reduces body weight in type 2 diabetes patients after 24 weeks of treatment.

29 May 2024

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.

29 May 2024

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.

28 May 2024

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Semaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.

28 May 2024

Taking semaglutide once weekly may lower the chances of kidney disease, says study

The effects of semaglutide (administered once weekly) on the outcomes of kidney disease.

28 May 2024

Phytochemicals show promise in treating neurological disorders by influencing the gut-brain axis

Researchers reviewed the potential therapeutic effects of phytochemicals on the gut-brain axis, finding they could influence brain function and reduce neurological symptoms by modulating gut microbiota.

26 May 2024

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

Researchers found that semaglutide treatment for weight loss in non-diabetic, obese men is associated with an increased risk of erectile dysfunction and testosterone deficiency.

26 May 2024

SELECT trial shows semaglutide reduces kidney decline in obese patients

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.

25 May 2024

Sharp uptick in youth using wegovy and ozempic, study reports

Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States are surprisingly scarce.

22 May 2024

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

Studies examining the risks of GLP-1 weight-loss drugs, distinguishing alpha-gal syndrome from other GI disorders, and comparing medications to slow the progression of liver disease in patients with alcohol-use disorder will be presented this week at Digestive Disease Week (DDW) 2024.

21 May 2024

Taurine supplementation shows promise in reducing metabolic syndrome risk factors, study finds

A study in Nutrition & Diabetes meta-analyzed randomized clinical trials and found that taurine supplementation significantly reduces key risk factors for metabolic syndrome, such as high blood pressure, fasting blood glucose, and triglycerides, with no notable adverse effects.

20 May 2024

From research to practice: Closing the divide in obesity management

As research continues to produce evidence about the underlying causes of obesity and optimal strategies to treat and manage obesity have evolved, there are disparities in application of the latest scientific advances in the clinical care that people with obesity receive.

20 May 2024

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models.

20 May 2024

Anti-obesity medications slash heart disease risk in obese patients, study finds

A study in the journal Obesity evaluated the impact of new anti-obesity medications (AOMs) on cardiovascular disease (CVD) among obese individuals, finding that these medications reduce the risk of CVD complications, particularly heart failure and atrial fibrillation.

15 May 2024

Sustainable weight loss with personalized semaglutide dosing

New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits of giving personalised doses of semaglutide to patients taking part in a weight loss programme and tapering them off the medication when they reach their target weight.

14 May 2024

Aerobic exercise proves most effective for combating obesity-related inflammation

New research being presented at this year's European Congress on Obesity (ECO) in Venice, Italy (12-15 May), reveals the anti-inflammatory power of moderate-to-vigorous aerobic exercise in adults living with the low-grade inflammation of obesity, shedding light on its potential to help prevent multiple metabolic diseases including type 2 diabetes and atherosclerosis (clogged arteries).

13 May 2024

Enhanced weight loss outcomes with GLP-1 analogues and bupropion/naltrexone combination

A study explores the additive effects of combining GLP-1 analog with bupropion/naltrexone on weight loss, finding potential benefits even for those initially unresponsive to monotherapy.

13 May 2024

Can monitoring and encouraging physical activity through phone-based apps improve glycemic control and weight loss in type 2 diabetes patients?

Whether a smartphone application (app) for maintaining personal health records encouraged physical activity, improved step counts, and glycemic control.

6 May 2024

Unveiling pancreatic mysteries: 3D imaging redefines islet cell distribution

Researchers at Umeå University have succeeded in imaging an entire human organ, a pancreas, in microscopic resolution.

22 Apr 2024

Metabolic health determines effectiveness of influenza vaccination

Metabolic health (normal blood pressure, blood sugar and cholesterol levels, among other factors) influences the effectiveness of influenza vaccinations. Vaccination is known to be less effective in people with obesity compared to those with a healthier body mass index (BMI), but St. Jude Children's Research Hospital scientists have found it is not obesity itself, but instead metabolic dysfunction, which makes the difference.

18 Apr 2024

Glucagon News and Research

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Taking semaglutide once weekly may lower the chances of kidney disease, says study

Phytochemicals show promise in treating neurological disorders by influencing the gut-brain axis

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

Sharp uptick in youth using wegovy and ozempic, study reports

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

Taurine supplementation shows promise in reducing metabolic syndrome risk factors, study finds

From research to practice: Closing the divide in obesity management

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Anti-obesity medications slash heart disease risk in obese patients, study finds

Sustainable weight loss with personalized semaglutide dosing

Aerobic exercise proves most effective for combating obesity-related inflammation

Enhanced weight loss outcomes with GLP-1 analogues and bupropion/naltrexone combination

Can monitoring and encouraging physical activity through phone-based apps improve glycemic control and weight loss in type 2 diabetes patients?

Unveiling pancreatic mysteries: 3D imaging redefines islet cell distribution

Metabolic health determines effectiveness of influenza vaccination

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News